Company profile · Biotech & medical
圓祥生技股份有限公司 · 6945
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
APBio develops new drugs focusing on mechanism-based drug design targeting tumor-associated antigens and the T-cube bispecific antibody platform.[1]
The company develops antibody and protein lead drugs for unmet medical needs.[2]
After subscribing, check your inbox (and spam folder) and confirm your subscription. We do this to protect you from spammers.
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$0m | – | – |
2024-11 to 2026-10, monthly revenue.
| Last 20 trading days | Net |
|---|---|
| 2026-10-15 to 2026-11-13 | +NT$14m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
| Full English name | AP Biosciences Inc |
|---|---|
| Chinese name | 圓祥生技股份有限公司 |
| Stock code | 6945 (TPEx) |
| Industry | Biotech & medical |
| Founded | 27 May 2013 |
| Listed | 05 Jun 2026 |
| Paid-in capital | NT$975m |
| Chairman | 陳志全 |
| President | 何正宏 |
| Headquarters | 11F-2,No508,Sec7,Zhongxao E Rd Taipei, Taiwan |
| Website | https://www.apbioinc.com |
| Official business description | 新藥研發 |
Facts from MOPS company basic information, retrieved 12 Nov 2026. The official business description is the company's own entry and can be out of date.
After subscribing, check your inbox (and spam folder) and confirm your subscription. We do this to protect you from spammers.
Generated 2026-11-15 00:39.